A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome

Phase 2

Withdrawn

• Conditions: Acute Respiratory Distress Syndrome
• Interventions: Drug: IC14; Other: Placebo

• Registration Number: NCT03017547
• Lead Sponsor: Implicit Bioscience

Brief Summary

Acute Respiratory Distress Syndrome (ARDS) patients will be randomized to receive either IC14 (a single dose of 4 mg/kg followed by 2 mg/kg on Days 2-4) or placebo. Study participation will be for a total of 28 days.

Detailed Description

Up to 160 patients with ARDS will be randomized to receive either IC14 at a dosage of 4 mg/kg on Study Day 1, then 2 mg/kg once daily on Study Days 2-4 or placebo for 4 days beginning within 48 hours of meeting inclusion criteria. Study participation will be for 28 days.

Study Timeline

• Study First Submitted: 2017-01-09
• Study First Submitted QC: 2017-01-09
• Study First Posted: 2017-01-11
• Status Verified: 2018-05
• Study Start: 2019-06-01
• Primary Completion: 2020-06
• Study Completion: 2020-06-01
• Last Update Submitted: 2025-08-15
• Last Update Posted: 2025-08-20

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. ICU admission

2. Age 18-70 years

3. Presence of a known ARDS clinical risk within 7 days of onset:

   1. Pneumonia
   2. Sepsis
   3. Trauma
   4. Aspiration
   5. Pancreatitis

4. Presence of ARDS (per Berlin criteria) defined as follows:

   1. Acute onset (<48 hours)
   2. PaO2/FiO2<300 on PEEP≥5
   3. Bilateral opacities consistent with pulmonary edema on frontal chest radiograph not fully explained by effusions, lobar/lung collapse, or nodules.
   4. Requirement for positive pressure ventilation via endotracheal tube

5. Anticipated duration of mechanical ventilation >48 hrs

Exclusion Criteria

1. Treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry

2. Intubation for cardiopulmonary arrest

3. Do-not-attempt resuscitation (DNAR) status

4. Intubation for status asthmaticus, pulmonary embolus, myocardial infarction

5. Anticipated survival <48 hours from intubation

6. Anticipated survival <28 days due to pre-existing medical condition

7. Significant pre-existing organ dysfunction

   1. Lung: Currently receiving home oxygen therapy as documented in medical record
   2. Heart: Pre-existing congestive heart failure defined as an ejection fraction <20% as documented in the medical record
   3. Renal: Chronic renal failure requiring renal replacement therapy
   4. Liver: Severe chronic liver disease defined as Child-Pugh Class C

8. Pre-existing, ongoing immunosuppression

   1. Solid organ transplant recipient
   2. Chronic high-dose corticosteroids (equivalent to >20 mg/prednisone/day for >14 days in the last 30 days)
   3. Oncolytic drug therapy within the past 14 days
   4. Known HIV positive with CD4 count <200 cells/mm3

9. Current treatment with Enbrel® (etanercept), Remicade® (infliximab), Humira® (adalimumab), Cimzia® (certolizumab), or Simponi® (golimumab), Kineret® (anakinra), or Arcalyst® (rilonacept)

10. Pregnancy

11. History of hypersensitivity or idiosyncratic reaction to IC14

12. Deprivation of freedom by administrative or court order

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
IC14	IC14	IC14 4 mg/kg IV on Study Day 1, then IC14 2 mg/kg IV once daily on Study Days 2-4.
Placebo	Placebo	Placebo IV once daily on Study Day 1-4

Primary Outcome Measures

Name	Time	Method
Safety	28 days	Treatment-emergent adverse events
Ventilator-free days	28 days	The number of days alive and free of mechanical ventilation through Day 28.

Secondary Outcome Measures

Name	Time	Method
Change in ARDS biologic markers.	28 days	* Change in plasma IL-8, sTNFR1, IL-6 from Day 0 to Day 4; * Change in alveolar neutrophils and total protein from Day 0 to Day 4